RecruitingPhase 1NCT05636579

Study to Assess Safety and Tolerability of Multiple Doses of EO2002

Phase 1, Multiple Dose, Open-Label Study to Assess the Safety and Tolerability of EO2002 Intracameral Injections With or Without Topical Ripasudil in the Treatment of Corneal Edema

Sponsor

Asociación para Evitar la Ceguera en México

Enrollment

12 participants

Start Date

Nov 8, 2022

Study Type

INTERVENTIONAL

Conditions

Endothelial Dysfunction Pseudophakic Bullous Keratopathy Fuchs' Endothelial Dystrophy Corneal Edema Fuchs Dystrophy Bullous Keratopathy Corneal Endothelial Dystrophy Corneal Edema Pseudophakic

Summary

The goal of this clinical study is to assess the safety of multiple intracameral injections of EO2002 with and without topical Ripasudil.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called EO2002 and a drug called Ripasudil for people with bullous keratopathy, corneal edema, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALEO2002

Intracameral injection of magnetic human corneal endothelial cells (EO2002)

DRUGRipasudil

Daily use of Ripasudil drops

Locations(1)

Asociacion para Evitar la Ceguera en Mexico

Mexico City, Mexico City, Mexico

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05636579

Related Trials

NightWare and Cardiovascular Health in Veterans With PTSD

NCT064199591 location

Samples From Human Subjects to Facilitate Basic, Translational and Clinical Research

NCT032537051 location